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comparator before entering negotiations. The negotiated price was between 0% and 
56% lower compared to the price listed in the AMNOG dossier, regardless of the level 
of additional benefit. The number of eligible patients for each drug (141 - 214,000) 
tends to correlate with the negotiated rebate. ConClusions: An additional benefit 
is necessary for a reimbursement beyond the reference group price. Despite the 
small number of observations it might be concluded, that the reimbursed price 
inversely correlates with disease incidence. The highest rebate on reimbursement 
price resulted from the decision of the arbitration board.
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objeCtives: Budget impact analysis is the traditional approach of assessing the 
affordability of new interventions. While vaccination has been shown to be one of 
the most cost-effective means to improve health, budget requirements can be a 
barrier. This study aims at comparing an affordability indicator of a new vaccine in 
countries with similar Gross Domestic Product (GDP) per capita, but different health 
care financing mechanisms. Methods: Based on National Health Accounts data, 
analyses of Total Health Expenditures (THE) and share of Public Health Expenditures 
(PHE) of various middle income countries were performed. Brazil and Turkey were 
selected for in-depth analysis as they had comparable GDPs and health care 
expenditures per capita. Health care access and financing data were also obtained 
from various government sources for a quantitative analysis. The budget require-
ments for a new vaccine costing $40 Purchasing Power Parity (PPP) per immunized 
child covering 80% of the birth cohort were calculated and expressed as a share of 
PHE. Results: THE per capita doubled over 10 years in both countries since 2001, 
reaching $1,037 (PPP) for Brazil and $1,160 for Turkey in 2011. However, the share of 
PHE is vastly different; 46% in Brazil compared to 75% in Turkey. Implementing the 
new vaccine would require an additional budget of $97Million and $42Million. While 
large in absolute values they represent only 0.11% of the PHE in Brazil and 0.07% in 
Turkey. The higher affordability in Turkey can be explained by a different financing 
mechanism. ConClusions: While the implementation of a new vaccine in com-
parable countries in terms of wealth and THE per capita would require significant 
additional national spending in absolute terms, it represents only a small fraction 
of the PHE. The underlying health care financing mechanisms is an important factor 
affecting the affordability of a new vaccination program.
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objeCtives: Since its adoption by the Institute for Quality and Efficiency in Health 
Care (IQWiG) in 2009, the Efficiency Frontier (EF) approach is criticized by the phar-
maceutical industry, key opinion leaders and national organizations. In a German 
context, we aim to verify the accuracy of those concerns. Methods: Review of the 
most commonly stated arguments against the EF-approach published within the 
scientific community and given as stakeholders’ response on IQWiG’s first cost-
effectiveness analysis of antidepressants. Results: Often stated objections against 
the EF include: 1) no international health economic standard, 2) merely disease 
specific without prioritization across disease areas, 3) no fixed threshold, and 4) 
avoiding the quality-adjusted life year (QALY). Ad 1): IQWiG adopted the EF-approach 
to inform setting appropriate reimbursement caps (since 2011 to inform negotia-
tions for appropriate reimbursement caps with an interquartile-range as basis). 
In other jurisdictions, an appropriate price need not be determined; decisions (or 
recommendations) are made regarding whether or not the cost-effectiveness of 
a drug supports (restricted) reimbursement. Ad 2+3): Although prioritizing funds 
is no primary aim in Germany, the EF can still be applied equally across indica-
tions. Within indications, the reimbursement cap may not distort competition by 
disadvantaging a manufacturer unfairly and needs to be appropriate when com-
pared with other available interventions. Contrary to the EF-approach, determining 
prices based on arbitrary fixed thresholds may not stand up in court. Ad 4): Despite 
methodological doubts concerning QALYs, they are not antecedently excluded as 
possible patient-relevant outcome measure when using the EF in Germany. Only 
a fixed cost/QALY-threshold was rejected. ConClusions: The EF fits the purpose 
of decision-making in Germany. Most objections are flawed or originate from a 
profound misunderstanding of the concept or the German (legal) context, where 
the EF is necessary and viable. The EF’s prime distinction remains: Deriving flexible, 
non-arbitrary thresholds for disease areas.
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objeCtives: A diagnostic test is any kind of medical test performed to aid in the 
diagnosis or detection of disease and is becoming a key component of Personalized 
Health Care (PHC). The market access and reimbursement pathways for pharmaceu-
ticals are well described however such pathways are missing for diagnostics in many 
countries and similarities between countries are not well understood. Methods: A 
targeted literature review has been executed on top of reviews from market access 
and reimbursement authorities in Germany, the UK and the US. Existing pathways 
were plotted and key decision criteria have been evaluated in terms of comparability 
and health care decison-maker impact. Results: In Germany inpatient reimburse-
ment is being differentiated from outpatient with inpatient access being easier to be 
achieved (DRG, OPS coding). The outpatient pathway includes a full evidence pack-
signs that a potential discount had lowered a list price in one of the other countries, 
but is it clear that despite the external reference price systems in Europe prices of 
high-priced therapies vary considerably.
PHP118
PublIc Preference elIcItAtIon In drug reImbursement usIng multI-
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objeCtives: To elicit public preference for drug reimbursement criteria in Korea’s 
universal health insurance system using three commonly used weighting methods 
in Multi-Criteria Decision-Analysis (MCDA). Methods: Based on literature review, 
we established five criteria in drugs reimbursement decision-making: disease 
impacts, context of reimbursement, improvement of health outcomes, economics 
and quality of evidence. We evaluated the relative importance of five criteria using 
three weighting methods of direct rating (DR), SWING and analytic hierarchy process 
(AHP). 283 people were selected across the country by quota sampling and asked to 
assess the weights of five criteria with all three weighting methods repeatedly. The 
survey was self-administered by the participants with help of the trained interview-
ers. Results: It was revealed that improvement of health outcomes and disease 
impacts have relatively higher weights than other three criteria in all weighting 
methods. Survey participants considered improvement of health outcomes the 
most important with DR (Mean [SD]: 0.210 [0.033]) and AHP (0.271 [0.127]), whereas 
disease impacts with SWING (0.231 [0.050]). Meanwhile, no coherence was shown 
in the low-ranked three criteria (context of reimbursement, economics, and quality 
of evidence) over three weighting methods. Quality of evidence ranked the third 
with DR (0.200 [0.035]), the fifth with SWING (0.165 [0.041]) and the fourth with AHP 
(0.160 [0.121]). Economics ranked the fourth with DR (0.197 [0.035]) and the third 
with SWING (0.192 [0.045]) and AHP (0.207 [0.118]). Lastly, context of reimbursement 
ranked the fifth with DR (0.188 [0.035]) and AHP (0.112 [0.090]) and the fourth with 
SWING (0.189 [0.045]). ConClusions: In this study, it was discovered that the sur-
vey participants considered improvement of health outcomes and disease impacts 
relatively more important than economics, context of reimbursement and quality 
of evidence in drug reimbursement decision making.
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objeCtives: This study explores current applications (and potential future use) 
of the Efficiency Frontier (EF) in health economic evaluation. Methods: We per-
formed desk research on pharmacoeconomic guidelines for current usage of the 
EF and investigated possibilities for future use. Results: Currently, the EF is offi-
cially used in 3 European countries. In Germany, since the enforcement of the ‘Act 
on the Reform of the Market for Medicinal Products’ (AMNOG) in January 2011, 
IQWiG applies the EF to determine non-arbitrary flexible thresholds across disease 
areas to ultimately determine an appropriate reimbursement price of new drugs 
(including interquartile-range to display uncertainty) in negotiations on request of 
the decision maker or manufacturer. In Belgium, the updated KCE guidelines dated 
July 2012 request the EF to identify the appropriate comparator among all relevant 
alternatives. In France, the updated HAS guidelines dated October 2012 require 
health interventions to be plotted on the EF to inform decision-making. In the 
future, the EF-approach could also be used to check on prices of national reference 
pricing clusters. Furthermore, the EF could help with priority setting (as suggested 
by the World Health Organization guide to cost-effectiveness analysis in 2003) and 
guiding or informing potential future (dis)investment decisions. The EF may also be 
combined with other approaches (e.g. making reimbursement decisions up to an 
ex ante fixed cost/outcome-threshold but setting prices beyond that level with the 
flexible EF). Lastly, it should not be overlooked that the EF can be applied for multiple 
purposes simultaneously. ConClusions: Since its first use to measure hospital 
efficiency, the EF is a valuable tool in health economics. Currently, its use diffuses 
within health economic evaluation and reimbursement decision-making. Yet, the 
full potential of the approach has not been exploited so far and the EF-approach 
remains under-researched by the scientific community.
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objeCtives: In January 2011 the new German law on the reorganization of the 
pharmaceutical market (AMNOG) came into force with the intention to reduce drug 
prices in Germany. Up to June 2013 44 dossiers completely evaluated and for 16 drugs 
(excluding orphan drugs) a price has been negotiated between the manufacturer and 
the National Association of Statutory Health Insurance Funds (GKV-SV). Since previ-
ous analyses have shown no correlation of negotiated price and the extent of clinical 
benefit, the underlying analysis aims to identify further parameters potentially 
influencing the reimbursed price of a new drug. Methods: Evaluated drugs with 
completed price negotiation between manufacturers and the GKV-SV were selected 
from the website of the Federal Joint Committee (G-BA). The manufacturer free 
price was analyzed for potential interactions with following parameters extracted 
from module 3 of the AMNOG dossier: number of eligible patients, annual drug cost 
of the evaluated intervention and appropriate comparator, and the final price as 
listed in the Lauer-Taxe (official German drug price index). Results: The 16 drugs, 
for which a negotiated reimbursement price was available, showed a minor (n= 8), 
considerable (n= 5), not quantifiable (n= 2) or no additional clinical benefit (n= 1).The 
investigated drug price was between 0,73 and 71 times the price of its appropriate 
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objeCtives: Moldova is a country where expenditure on pharmaceuticals is already 
very high and exceeds several times the prices in the region. Drugs expenditure 
represents 70% of direct health expenditure of a household and is the main factor 
that reduces the financial protection of health care services. The objective of the 
study was to assess affordability of reimbursement medicines and to evaluate the 
National Health Insurance Company (NHIC) impact on ensuring economic accessibil-
ity. Methods: To determine the affordability of medicines was used the methodology 
recommended by the World Health Organization. Have been analyzed data concern-
ing price of drugs, the amounts paid by patients and the amounts paid by the NHIC 
for partially reimbursed drugs for 5 years (2008-2012). Was calculated: the median 
price for each drug international common name dependent’s on strength; duration of 
treatment and number of units needed for treatment (for chronic disease); number of 
working days required for a treatment cure depending on minimum wage and aver-
age wage in economy. Available treatment is considered, the cost of which is 1 or less 
than the cost of one working day. Based on these results has been also determined 
the impact of the NHIC. Results: Number of economically accessible reimbursed 
drugs depending on minimum wage was: 2008-24 (42%), 2009-34 (60%), 2010-43 (53%), 
2011-48 (58%), and 2012-71 (86%); depending on average wage in economy: 2008-50 
(87%), 2009-50 (87%), 2010-66 (81%), 2011-73 (88%), and 2012-77(94%). The average num-
ber of working days compensated by NHIC based on the minimum wage: 2008-6.23, 
2009-3.5, 2010-3.7, 2011-2.92, and 2012-1.03; based on average wage in economy: 2008-
0.98, 2009-0.76, 2010-0.75, 2011-0.55, and 2012-0.38. ConClusions: Compensation 
of drugs by NHIC, doesn’t significantly affect the affordability of reimbursement 
medicines. Patients feels no real benefit from NHIC, drugs expenditure within the 
households practically remain unchanged even if it get reimbursed medicines.
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objeCtives: To assess the methodological quality of economic evaluations included 
in Belgian reimbursement applications for Class 1 drugs. Methods: For 19 reim-
bursement applications submitted during 2011 and Spring 2012, a descriptive analy-
sis assessed the methodological quality of the economic evaluation, evaluated the 
assessment of that economic evaluation by the Drug Reimbursement Committee 
and the response to that assessment by the company. Compliance with methodo-
logical guidelines issued by the Belgian Healthcare Knowledge Centre was assessed 
using a detailed checklist of 23 methodological items. The rate of compliance was 
calculated based on the number of economic evaluations for which the item was 
applicable. Results: Economic evaluations tended to comply with guidelines 
regarding perspective, target population, subgroup analyses, comparator, use of 
comparative clinical data and final outcome measures, calculation of costs, incre-
mental analysis, discounting and time horizon. However, more attention needs to 
be paid to the description of limitations of indirect comparisons, the choice of an 
appropriate analytic technique, the expression of unit costs in values for the cur-
rent year, the estimation and valuation of outcomes, the presentation of results of 
sensitivity analyses, and testing the face validity of model inputs and outputs. Also, 
a large variation was observed in the scope and depth of the quality assessment by 
the Drug Reimbursement Committee. ConClusions: Although general guidelines 
exist, pharmaceutical companies and the Drug Reimbursement Committee would 
benefit from the existence of a more detailed checklist of methodological items that 
need to be reported in an economic evaluation.
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objeCtives: In the CZ, orphan drugs so-called highly innovative drugs first enter 
a temporary reimbursement period of three years. Having proven their cost-effec-
tiveness they later become permanently reimbursed. The objective of the study 
was to determine how successfully orphan drugs enter the database of reimbursed 
drugs. Methods: The EMA list of orphan drugs was compared to the Czech data-
base of reimbursed drugs to the date of 1-Jul-2013. For each detected drug the date 
of entering the database was found. In drugs reimbursed after 2008, submissions 
of cost effectiveness analyses were recorded. Although CZ has no willingness to 
pay threshold, interpretation of cost effectiveness analyses results could improve 
the process of HTA of drugs. Results: To the date of 1-Apr-2013 the EMA has 
registered 65 orphan drugs. Out of these, 28 have been assigned a maximum and 
reimbursement price in the CZ. To this date, 27 drugs have not applied for reimburse-
ment price. Starting from 2008, 30 drugs have applied: in 20 products the decision 
is legally effective, in 2 cases only hospital use has been approved, in 7 cases (3 
appeals, 4 unfinished proceedings) the proceedings are still in process and in one 
case the application was withdrawn. In about a third of cases a cost effectiveness 
analysis was submitted and accepted by SUKL. The upper limit of the ICER of the 
submitted analyses exceeds by far the cost-effectiveness level recommended by the 
WHO. ConClusions: The results imply that in almost in all cases the submitted 
applications for maximum and reimbursement price are approved by SUKL. In some 
cases, however, the health insurance companies hinder reimbursement of drugs 
by filing an appeal. However, the assessment of cost effectiveness of drugs should 
be performed at an earlier level – during the administrative proceedings. This calls 
for necessary emphasis on health technology assessment.
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age including clinical and health economic data and takes on average more than 
two years. In the UK the process is largely based on three different PCT payment 
and the various NHS value for money mechanisms combined with procurement 
systems. The value-based pricing system might change the current situation. Finally, 
in the US CPT codes are similarly being applied as DRG codes in Germany with 
a different pathway of application. In comparison the health economic evidence 
plays a larger role in the UK, even though (still) not in a systematic manner as for 
pharmaceuticals. The clinical evidence plays an important role in all countries, 
however it was identified that for diagnostic tests the access routes and especially 
the coding process is more dependent on consistency on applicability of existing 
codes and technology argumentation. ConClusions: In the different countries 
the evidence base for market access and reimbursement pathways for diagnostics 
differs significantly. Instead, having a unified approach might ease a value based 
market access argumentation for diagnostics.
PHP126
A comPArAtIVe study of tHe role of dIseAse seVerIty In drug 
reImbursement decIsIon mAkIng In belgIum, frAnce, tHe netHerlAnds 
And sweden
Franken M., Koopmanschap M.
Erasmus University, Rotterdam, The Netherlands
objeCtives: Considerations beyond (cost-) effectiveness are increasingly important 
in reimbursement decision-making. We investigated the importance of disease sever-
ity relatively to other decision criteria in drug reimbursement decision-making in four 
European countries. Methods: The importance of disease severity and its operation-
alization was assessed in Belgium, France, The Netherlands and Sweden. We investi-
gated scientific literature, policy documents, reimbursement reports, and conducted 
three interviews in each country (four in The Netherlands) with policymakers involved 
in drug reimbursement. Results: All interviewees acknowledged that disease sever-
ity is, especially in case of high severity, an important criterion while considering 
a drug’s (cost-) effectiveness. However, its relative importance compared to other 
decision criteria remains implicit in the decision-making process. Although rarity of 
the disease is not a criterion as such, interviewees indicated difficulties in separating 
rarity from severity and the availability of alternative treatments. Only Belgium and 
France explicitly show societal willingness to pay by using reimbursement levels 
depending on the severity of the disease. In Sweden, ‘need and solidarity’ is one 
of the three prioritizing principles. The Netherlands is the only country that quan-
titatively operationalized disease severity using the proportional shortfall method 
and suggesting a cost-effectiveness threshold range depending on disease severity 
(which was never formalised by the minister). Although interviewees acknowledged 
that quantitative information, besides a qualitative description of the disease, may 
provide additional decision information, none of them considered such information 
to be of decisive importance. ConClusions: Disease severity is, especially in case 
of high severity, an important decision criterion in all four countries. However, all 
countries seem to struggle in making its actual role explicit. The operationalization 
differs across countries. While Belgium and France are most explicit by using the 
severity of the disease in setting reimbursement levels, all countries could improve 
transparency of its actual importance relatively to other decision criteria.
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objeCtives: To evaluate the clinical and health economic evidence requirements 
for obtaining statutory health insurance coverage for innovative medical devices 
(MDs) in Germany. Methods: We have assessed the requirements for innovative 
MDs in Germany according to the available reimbursement pathways and grouped 
them by the application setting as this had a significant impact on the research 
question. Results: According to the German statutory rules in the inpatient care 
setting (reservation of prohibition; ‘Verbotsvorbehalt’) all innovative MDs can be 
applied once they have received marketing approval for Germany (CE mark) whereas 
a positive voting from the federal joint committee is required before MDs can be 
applied in the outpatient setting (reservation of authorization; ‚Erlaubnisvorbehalt’). 
The reimbursement coverage in the inpatient setting depends on the available cod-
ing and grouping mechanisms that define specific diagnoses related groups and 
their reimbursement value. If this value is not adequate or an adequate coding/
grouping is not possible specific applications can be made, that require no specific 
clinical and health economic evidence; only a detailed (additional) cost estimation 
of the new procedure and a rationale of the innovative character are required. In 
contrast the outpatient reimbursement of the statutory health insurance shows 
very strict requirements as a detailed clinical evidence reporting (e.g. randomized-
controlled trials) and a full health economic evaluation (e.g. cost-effectiveness and 
budget impact assessment) need to be provided for obtaining reimbursement cov-
erage. There are recent political streams that claim that the regulatory and reim-
bursement process of MDs should be adapted comparable to the more restrictive 
regulations for pharmaceuticals which might have a major impact on the evidence 
requirements for the inpatient sector. ConClusions: Currently MDs applied in the 
inpatient setting require no specific evidence whereas strong clinical and health 
economic evidence is required for MDs applied in the outpatient setting.
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